ETV3
Overview
ETV3 is an ETS family transcription factor that functions as a transcriptional repressor. In prostate cancer, ETV3 harbors deleterious somatic mutations (frameshift and nonsense) identified by whole-exome sequencing of castration-resistant prostate cancer. As an ETS family member distinct from the oncogenic fusion genes (ERG, ETV1, ETV5), ETV3 mutations may represent loss-of-function events with tumor suppressive consequences.
Alterations observed in the corpus
- ETV3 harbors deleterious somatic mutations (P327fs frameshift and W38* nonsense) in 2 castration-resistant prostate cancers (CRPCs) from the Michigan WES cohort (112 tumors total) PMID:22722839
- Co-deleted with ETV6 and CDKN1B in a 25-rearrangement chromoplexy chain in prostate cancer PMID:23622249
Cancer types (linked)
- PRAD: ETV3 frameshift (P327fs) and nonsense (W38*) mutations identified in CRPC; both are predicted loss-of-function alterations, consistent with a tumor suppressive role for ETV3 in the ETS-driven prostate cancer landscape PMID:22722839
Co-occurrence and mutual exclusivity
- ETV3 mutations occur in the context of broader ETS family dysregulation in prostate cancer, where oncogenic ETS fusions (ERG, ETV1, ETV5) are common; the relationship between ETV3 loss and ETS fusion status in individual tumors is not yet characterized PMID:22722839
Therapeutic relevance
- No direct therapeutic targeting of ETV3 reported. ETV3 loss may contribute to ETS transcriptional network imbalance in prostate cancer; implications for ETS-directed therapeutic approaches are unclear PMID:22722839
Open questions
- Functional consequences of P327fs and W38* mutations in ETV3 have not been validated in prostate cancer models
- Prevalence of ETV3 mutations in larger prostate cancer cohorts and in localized (non-CRPC) disease is not established
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:23622249
This page was processed by crosslinker on 2026-05-09.